Patent Extensions. Primary shall promptly notify Legacy of the issuance of each Regulatory Approval concerning a Primary Collaboration Derived Product in the Primary Field and, where reasonably possible and reasonably useful or materially valuable in the commercialization of Primary Collaboration Derived Products in the Primary Field, use Commercially Reasonable Efforts to apply or enable Legacy to apply for all available patent term extensions, adjustments or restorations, or supplementary protection certificates with respect to any Legacy Patents Covering such Primary Collaboration Derived Products (or CDC(s) or Derivative(s) thereof contained therein), or other forms of market exclusivity conferred by Applicable Laws on any Primary Collaboration Derived Products (or CDC(s) or Derivative(s) thereof contained therein) (collectively, all of the foregoing, “Legacy Patent Term Extensions”). Legacy shall, to the extent reasonably possible and reasonably useful or valuable in the commercialization of Primary Collaboration Derived Products, use Commercially Reasonable Efforts to, if and as requested by Primary, obtain (or assist Primary in obtaining), with respect to the Legacy Patents, all Legacy Patent Extensions in any country of the Territory. The Parties shall cooperate with each other in obtaining Legacy Patent Term Extensions wherever and whenever applicable, reasonably possible to obtain, and reasonably useful or valuable in the commercialization of Primary Collaboration Derived Products.

Legacy shall promptly notify Primary of the issuance of each Regulatory Approval concerning a Viamet Derived Product and, where reasonably possible and reasonably useful or materially valuable in the commercialization of any Viamet Derived Products, Primary shall, to the extent reasonably possible and reasonably useful or valuable therein, use Commercially Reasonable Efforts to, if and as requested by Legacy and at Legacy’s expense, obtain (or assist Legacy in obtaining), with respect to the Licensed Primary Patents, all available patent term extensions, adjustments or restorations, supplementary protection certificates, or other forms of market exclusivity conferred by Applicable Laws (collectively, “Primary Patent Term Extensions”) in any country of the Territory. The Parties shall cooperate with each other (at Legacy’s expense) in obtaining Primary Patent Term Extensions wherever and whenever applicable, reasonably possible to obtain, and reasonably useful or valuable in the commercialization of any Viamet Derived Product.